Prescribing Information is available here. Adverse Event reporting can be found in the footer.
Shifting the focus to prevention
Protecting bone health in an ageing population. Accrete®-D3 is indicated for the prevention and treatment of vitamin D and calcium deficiency in the elderly, and adjunct to specific osteoporosis treatments of patients who are at risk of vitamin D and calcium deficiency.1,2
A cost-effective calcium + vitamin D treatment for your patients. Offering a choice of swallowable and chewable tablets.1,2
Access in-year savings with Accrete®-D3: Find out how much your health economy could save by viewing the cost-savings calculator.
The most cost-effective calcium + vitamin D brand offering a choice of chewable One a Day and swallowable twice daily tablets3
A cost-saving alternative without compromise: Provides savings of up to 35% vs Adcal-D3® Chewable Tablets (56 pack)3
Empowering patient preference: Available in chewable once-daily or swallowable twice-daily formats1,2
Access in-year savings with Accrete®-D3: Find out how much your health economy could save by viewing the cost-savings calculator
Improved bone health = reduced burden on patients and the NHS,
as a result of fewer fragility fracture-related hospital admissions4
As the UK population ages, there is an increased prevalence for age-related diseases, particularly bone mineral deficiencies, osteoporosis and fragility fractures.5 Efficient prevention and treatment of osteoporosis should include calcium and vitamin D supplementation.6
Almost
50%
of people aged 80 have osteoporosis. Osteoporosis prevalence rises steeply with age – from just 2% at age 50 to nearly 50% by age 807
Approximately
2M
women in the UK are affected by osteoporosis. Women are at far greater risk than men, making osteoporosis one of the most common chronic conditions7
At least
1
osteoporotic fracture sustained by > 1 in 3 women and > 1 in 5 men7
Approximately
£4.6Bn
annual cost of osteoporotic fractures to the NHS. These costs are projected to rise to £6 billion by 2030, driven by an ageing population and increasing fracture rates8
In-year cost savings allow reinvestment into wider patient care
Accrete®-D3 provides savings of up to 35% vs Adcal-D3® Chewable Tablets (56 pack). The cost of either formulation is just £3.58 for 30 days, this is equivalent to approximately £43.56 per year.3
Find out how much your health economy could save in a year with Accrete®-D3 by downloading an instant cost-saving calculator report.
Two formulations support patient choice and adherence1,2
Poor/non-adherence to osteoporosis medication lead to ~ 50% reduction in potential medication benefits, resulting in an increased frequency of fractures, whilst drastically reducing the cost-effectiveness of medication.9
Flavour, texture, and pill burden can impact on adherence. Patient preference is an important way to support treatment persistence.10,11
To improve medication compliance, prescribers can:
Help patients feel involved in their treatment11
Consider the impact of flavour, texture, and number of pills12
Consider once-daily dosing options instead of multiple daily doses13
Consider personalised and evidence based daily dosing1,2,14
Patient Guides
Sign up now for an instant download of the Accrete®-D3 Patient Guide, offering valuable information to help your patients understand the importance of staying consistent with their calcium and vitamin D treatment, along with practical tips to improve their overall bone health.
References
1. Accrete®-D3 film-coated tablets SmPC. 2. Accrete®-D3 One a Day 1000 mg / 880 IU Chewable Tablets SmPC. 3. NHS. Dictionary of Medicines + Devices (DM+D). Accessed: April 2026. 4. UK Parliament. PRI0158: Written evidence submitted Royal Osteoporosis Society. Accessed: April 2026. 5. Kirkham-Wilson F, Dennison E. Royal Osteoporosis Society: Epidemiology of Osteoporotic Fracture: an overview. Accessed: April 2026. 6. Carugo S, et al. Arch Osteoporos. 2024;19(1):99. 7. NICE Clinical Knowledge Summaries (CKS). Osteoporosis – prevention of fragility fractures: How common is it? Accessed: April 2026. 8. UK Parliament. ICS0035: Written evidence submitted Royal Osteoporosis Society (2022). Accessed: April 2026. 9. Hiligsmann M, et al. Value Health. 2012;15(5):604-12. 10. Shariff Z, et al. Pharmaceutics. 2020;12(10):905. 11. Martin LR, et al. Ther Clin Risk Manag. 2005;1(3):189-99. 12. Shariff ZB, et al. J Am Med Dir Assoc. 2020;21(8):1015-1023.e8. 13. Farrell B, et al. Can Pharm J (Ott). 2013;146(5):262–69. 14. Bone Health & Osteoporosis Foundation. Calcium and Vitamin D. Accessed: April 2026.